<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id>
<journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id>
<journal-title-group>
<journal-title>Journal of Neuroinflammation</journal-title>
</journal-title-group>
<issn pub-type="epub">1742-2094</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31519175</article-id>
<article-id pub-id-type="pmc">6744684</article-id>
<article-id pub-id-type="publisher-id">1564</article-id>
<article-id pub-id-type="doi">10.1186/s12974-019-1564-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The endotoxin hypothesis of neurodegeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3610-1730</contrib-id>
<name>
<surname>Brown</surname>
<given-names>Guy C.</given-names>
</name>
<address>
<email>gcb3@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Department of Biochemistry, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, CB2 1QW UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>13</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>16</volume>
<elocation-id>180</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The endotoxin hypothesis of neurodegeneration is the hypothesis that endotoxin causes or contributes to neurodegeneration. Endotoxin is a lipopolysaccharide (LPS), constituting much of the outer membrane of gram-negative bacteria, present at high concentrations in gut, gums and skin and in other tissue during bacterial infection. Blood plasma levels of endotoxin are normally low, but are elevated during infections, gut inflammation, gum disease and neurodegenerative disease. Adding endotoxin at such levels to blood of healthy humans induces systemic inflammation and brain microglial activation. Adding high levels of endotoxin to the blood or body of rodents induces microglial activation, priming and/or tolerance, memory deficits and loss of brain synapses and neurons. Endotoxin promotes amyloid β and tau aggregation and neuropathology, suggesting the possibility that endotoxin synergises with different aggregable proteins to give different neurodegenerative diseases. Blood and brain endotoxin levels are elevated in Alzheimer’s disease, which is accelerated by systemic infections, including gum disease. Endotoxin binds directly to APOE, and the APOE4 variant both sensitises to endotoxin and predisposes to Alzheimer’s disease. Intestinal permeability increases early in Parkinson’s disease, and injection of endotoxin into mice induces α-synuclein production and aggregation, as well as loss of dopaminergic neurons in the substantia nigra. The gut microbiome changes in Parkinson’s disease, and changing the endotoxin-producing bacterial species can affect the disease in patients and mouse models. Blood endotoxin is elevated in amyotrophic lateral sclerosis, and endotoxin promotes TDP-43 aggregation and neuropathology. Peripheral diseases that elevate blood endotoxin, such as sepsis, AIDS and liver failure, also result in neurodegeneration. Endotoxin directly and indirectly activates microglia that damage neurons via nitric oxide, oxidants and cytokines, and by phagocytosis of synapses and neurons. The endotoxin hypothesis is unproven, but if correct, then neurodegeneration may be reduced by decreasing endotoxin levels or endotoxin-induced neuroinflammation.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Endotoxin</kwd>
<kwd>Neurodegeneration</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>Microglia</kwd>
<kwd>Inflammation</kwd>
<kwd>Neuroinflammation</kwd>
<kwd>Lipopolysaccharide</kwd>
<kwd>Gut microbiome</kwd>
<kwd>Bacteria</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id>
<institution>Wellcome Trust</institution>
</institution-wrap>
</funding-source>
<award-id>RG50995</award-id>
<principal-award-recipient>
<name>
<surname>Brown</surname>
<given-names>Guy C.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010767</institution-id>
<institution>Innovative Medicines Initiative</institution>
</institution-wrap>
</funding-source>
<award-id>115976</award-id>
<principal-award-recipient>
<name>
<surname>Brown</surname>
<given-names>Guy C.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id>
<institution>Medical Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>MR/L010593</award-id>
<principal-award-recipient>
<name>
<surname>Brown</surname>
<given-names>Guy C.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002283</institution-id>
<institution>Alzheimer’s Research UK</institution>
</institution-wrap>
</funding-source>
<award-id>RG91100</award-id>
<principal-award-recipient>
<name>
<surname>Brown</surname>
<given-names>Guy C.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par29">Neurodegeneration is progressive damage and death of neurons, normally as a result of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Genetics affects the risk of these diseases, but there is a strong non-genetic contribution to the risk, which is poorly understood [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. There is accumulating evidence (reviewed below) that one of these non-genetic triggers for neurodegeneration is endotoxin. Endotoxin is present in all of us, but levels in blood are very variable and correlate with neurodegeneration. Injection of endotoxin into animals can induce neurodegeneration. So, the hypothesis that endotoxin causes or contributes to neurodegeneration is described and reviewed here, in the hope that a more explicit statement of the hypothesis will encourage testing of it.</p>
</sec>
<sec id="Sec2">
<title>Endotoxin structure and function</title>
<p id="Par30">Endotoxin is a type of lipopolysaccharide (LPS), consisting of lipid A (usually 6 acyl chains attached to a phosphorylated disaccharide), attached to the ‘core’ (a short sugar chain with various modifications), which is attached to the O-antigen (a long linear chain of sugars of variable length). Endotoxin is a major component of the outer membrane of gram-negative bacteria, with lipid A in the membrane and the O-antigen constituting the outer-facing surface of the bacterium. Soluble endotoxin is released when bacteria are destroyed, but is also released physiologically as outer membrane vesicles.</p>
<p id="Par31">Different species of gram-negative bacteria have different endotoxin structures, mainly due to differences in (i) the O-antigen, which determines the antigenicity of endotoxin, or (ii) lipid A, which is detected by the main LPS receptor MD2/TLR4 (a complex of myeloid differentiation factor 2 and toll-like receptor 4) and therefore determines inflammation and toxicity [<xref ref-type="bibr" rid="CR3">3</xref>]. Thus, not all endotoxins are equivalent. LPS toxicity varies depending on lipid A composition, and this depends on bacterial species, strain and environmental conditions [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. For example, the opportunistic lung pathogen <italic>Pseudomonas aeruginosa</italic> changes its lipid A structure from 5 to 6 acyl chains in response to cystic fibrosis, and the resulting hexa-acylated LPS activates MD2/TLR4 much more strongly than penta-acylated LPS [<xref ref-type="bibr" rid="CR4">4</xref>]. Both <italic>Escherichia coli</italic> and <italic>Bacteroides dorei</italic> are common in human gut, but LPS from <italic>E. coli</italic> has 6 acyl chains in the lipid A, whereas <italic>B. dorei</italic> LPS has 4 or 5 acyl chains, and as a consequence, <italic>E. coli</italic> LPS induces a strong inflammatory response via MD2/TLR4, whereas <italic>B. dorei</italic> LPS does not [<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, because <italic>B. dorei</italic> LPS binds but does not activate the MD2/TLR4 receptor complex, it can inhibit the inflammatory response to <italic>E. coli</italic> LPS [<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, some LPS species are MD2/TLR4 antagonists, and hence anti-inflammatory, as a result of binding but not activating MD2 and/or TLR4 [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par32">Gram-negative bacteria, containing endotoxin, are found at very high levels in the mammalian gut (mainly lower intestine) [<xref ref-type="bibr" rid="CR6">6</xref>]. They are also found in saliva, dental plaque, skin, lungs, respiratory tract and urinary tract. There is very roughly 1 g of endotoxin in the human gut [<xref ref-type="bibr" rid="CR6">6</xref>], whereas 100 ng of endotoxin injected into blood induces inflammatory activation of the body and brain (Table <xref ref-type="table" rid="Tab1">1</xref>). Humans are orders of magnitude more sensitive to endotoxin than other mammals, such as mice [<xref ref-type="bibr" rid="CR16">16</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Plasma endotoxin levels in different conditions and endotoxin levels causing various effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Condition</th><th>Endotoxin level</th><th>Ref:</th></tr></thead><tbody><tr><td>Healthy humans</td><td>10 ± 20 pg/ml</td><td>[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>Atherosclerosis</td><td>30 pg/ml</td><td>[<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>Peridonitis</td><td>45 pg/ml</td><td>[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td>Amyotrophic lateral sclerosis</td><td>45 pg/ml</td><td>[<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td>Liver cirrhosis</td><td>60 pg/ml</td><td>[<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>Alzheimer’s disease</td><td>60 pg/ml</td><td>[<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td>HIV infection/AIDS</td><td>70 pg/ml</td><td>[<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td>Sepsis</td><td>500 pg/ml</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>Monocyte and endothelial activation</td><td>10 pg/ml (added to isolated blood)</td><td>[<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td>Microglial activation, blood cytokines and sickness behaviour</td><td>1 ng/kg (~ 15 pg/ml, iv injected)</td><td>[<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr></tbody></table></table-wrap></p>
<p id="Par33">Endotoxin causes inflammatory activation mainly via activating TLR4 (with co-receptor MD2) on the cell surface, resulting in NF-κB transcriptional activation of hundreds of inflammatory genes, including pro-inflammatory cytokines such as TNFα, IL-6 and pro-IL-1β [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Lipopolysaccharide binding protein (LBP) is a soluble plasma protein that facilitates the transfer of LPS to membrane-bound CD14, which in turn is required to transfer LPS to TLR4 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Intracellular LPS can also directly activate murine caspase-11 (caspase-4 or caspase-5 in humans), which may then cleave and activate caspase-1, which can cleave pro-IL-1β to IL-1β [<xref ref-type="bibr" rid="CR20">20</xref>]. Active caspase-1 and caspase-11 can also cleave and activate gasdermin D that permeabilises the plasma membrane allowing IL-1β out, but also killing cells by pyroptosis [<xref ref-type="bibr" rid="CR20">20</xref>]. Other receptors for endotoxin include RAGE [<xref ref-type="bibr" rid="CR21">21</xref>], TREM2 [<xref ref-type="bibr" rid="CR22">22</xref>], the macrophage scavenger receptors [<xref ref-type="bibr" rid="CR23">23</xref>] and the β<sub>2</sub> integrins (CD11a/CD18, CD11b/CD18 and CD11c/CD18) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. These pattern recognition receptors may function to clear LPS and bacteria expressing LPS from blood and tissues [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], but may also promote inflammation and LPS toxicity [<xref ref-type="bibr" rid="CR21">21</xref>]. For example, CD11b/CD18 (also known as compliment receptor 3, CR3) mediates microglial ROS production, neurotoxicity and phagocytosis of neurons, and CR3 is implicated in neurodegeneration [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p id="Par34">High doses of endotoxin in blood (endotoxemia) cause a ‘cytokine storm’, septic shock and death, via activating TLR4, RAGE and caspases [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Chronic low doses of endotoxin can either promote low-grade inflammation, tolerance or resolution, depending on other factors [<xref ref-type="bibr" rid="CR17">17</xref>]. Endotoxin also induces inflammation and other effects indirectly via the pro-inflammatory cytokines TNFα, IL-6 and IL-1β induced by endotoxin. Note, however, that cytokine induction by endotoxin depends on the lipid A structure [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par35">Endotoxin was originally called ‘endotoxin’, because it was a toxin within the bacteria, to distinguish it from ‘exotoxins’ that were released from bacteria. However, we now know that (i) endotoxin is released by bacteria and (ii) the toxicity of endotoxin is due to the host’s inflammatory over-reaction to it, rather than an intrinsic toxicity to animal cells [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. LPS constitutes much of the surface of gram-negative bacteria, and thus, animals selected by bacterial diseases have evolved innate immune receptors to detect it with high sensitivity, inducing a strong innate (and adaptive) immune response. This response protects against gram-negative bacterial disease, by promoting the clearance of the bacteria, removing the source of endotoxin. However, (i) if endotoxin levels are too high, they cause acute death by septic shock, and (ii) if endotoxin is not cleared from the blood, it can promote a chronic inflammatory state, which may contribute to multiple chronic diseases [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>The central pathway of how endotoxin leads to neurodegeneration. Gut endotoxin may enter blood due to leaky gut, e.g. due to alpha-synuclein aggregates. Gum endotoxin may enter blood as a result of gum inflammation or tooth brushing. Blood endotoxin may cause brain inflammation via blood or brain cytokines, or by entering the brain, resulting in neurodegeneration</p></caption><graphic id="MO1" xlink:href="12974_2019_1564_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec3">
<title>Serum endotoxin</title>
<p id="Par36">Endotoxin is present in plasma of all healthy humans at very variable levels between 0.01 and 0.5 EU/ml (mean 0.1 ± 0.2 EU/ml), equivalent to about 1 and 50 pg/ml [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Note that endotoxin levels are normally measured using a Limulus amebocyte lysate assay (LAL-test) in endotoxin units (EU), a measure of activity not amount, and there are normally between 2 and 50 EU/ng endotoxin, because different endotoxins have different activities (i.e. potencies in the LAL test). Care is required when applying the LAL to blood, as blood components can interfere [<xref ref-type="bibr" rid="CR29">29</xref>]. Note also that basal plasma levels of endotoxin in rodents are higher than humans (typically 2 EU/ml) and rodents are much less sensitive than humans to injected endotoxin [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par37">Serum endotoxin levels are elevated in patients with severe autism [<xref ref-type="bibr" rid="CR30">30</xref>], liver cirrhosis [<xref ref-type="bibr" rid="CR11">11</xref>], diabetes [<xref ref-type="bibr" rid="CR31">31</xref>], cardiovascular disease [<xref ref-type="bibr" rid="CR8">8</xref>], chronic infection and ageing [<xref ref-type="bibr" rid="CR32">32</xref>], amyotrophic lateral sclerosis and Alzheimer’s disease [<xref ref-type="bibr" rid="CR10">10</xref>]. The highest plasma endotoxin levels are found in patients with sepsis, about 500 pg/ml [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
<p id="Par38">How much blood endotoxin is required to cause a significant effect in the body and brain? Addition of 10 pg endotoxin/ml to human blood is sufficient to activate monocytes and endothelial cells [<xref ref-type="bibr" rid="CR14">14</xref>]. Intravenous injection of 1 ng LPS/kg (equivalent to 15 pg/ml distributed through the blood) into healthy human volunteers caused increased blood cytokines (TNFα, IL-6, IL-8, IL-10), increased sickness behaviour (fatigue, headache, muscle pain, shivering) and decreased motivation (alertness, energy, focus, pep, social interest) within 1–3 h, reversing at 4 h [<xref ref-type="bibr" rid="CR15">15</xref>]. Importantly, this intravenous injection of 1 ng LPS/kg caused a robust microglial activation in most areas of the brain measured by PET (positron emission tomography) imaging of a PBR (peripheral benzodiazepine receptor) ligand 3 h after LPS injection [<xref ref-type="bibr" rid="CR15">15</xref>]. Thus, a relatively mild dose of blood endotoxin (e.g. less than that found in Alzheimer’s patients) can cause acute microglial activation within the brain. Note, however, that (at least in mice) repeated doses of LPS greatly downregulate body responses to LPS, but brain responses to LPS are less downregulated, partly as a result of epigenetic changes [<xref ref-type="bibr" rid="CR33">33</xref>]. So, it is difficult to extrapolate the chronic response to blood endotoxin from the acute response. Untreated healthy humans with blood endotoxin at the top end of the normal range have activated monocytes and T cells, with constitutive activation of the transcription factor STAT1 [<xref ref-type="bibr" rid="CR34">34</xref>]. Thus, the very variable, normal range of blood endotoxin in humans includes levels sufficient to activate the innate immune system.</p>
<p id="Par39">Where does blood endotoxin come from? Active bacterial infections may produce endotoxin, and for example, urinary tract infections are associated with dementia, delirium and other neuropsychiatric disorders [<xref ref-type="bibr" rid="CR35">35</xref>]. However, in the absence of infection, endotoxin still crosses the mucosal membranes of gut, gums, nose or lungs, the main source being intestinal permeability [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
<p id="Par40">Endotoxin has a hydrophobic lipid A end, so endotoxin aggregates into micelles or vesicles. Within the blood, endotoxin binds to plasma albumin or chylomicrons or high-density lipoproteins (HDL) mediated by LBP, CD14 and APOE [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. Most endotoxin enters the body via the gut and hepatic portal vein, and most of this endotoxin is cleared by the liver [<xref ref-type="bibr" rid="CR41">41</xref>]. Peripheral blood endotoxin is also cleared and degraded by the liver [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. So, serious liver disease increases peripheral blood endotoxin to potentially toxic levels (60–80 pg/ml in cirrhosis) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p>
</sec>
<sec id="Sec4">
<title>Peripheral endotoxin can drive brain pathology</title>
<p id="Par41">Does endotoxin in blood cause neurodegeneration? It is not ethical to test this directly in humans, but this question has been tested in animals.</p>
<p id="Par42">In rodents, a single intraperitoneal injection of 5 mg LPS/kg causes acute microglial activation in the brains that persists for at least 12 months, and results in loss of dopaminergic neurons in the substantia nigra 10 months later [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Multiple doses of 1 mg LPS/kg (over several days), or chronic endotoxin, cause more rapid neurodegeneration and have been used as models of Parkinson’s or Alzheimer’s disease [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Direct injection of LPS into the rodent brain is sufficient to induce neuronal loss [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Note, however, that (i) these levels of endotoxin would be lethal in humans; (ii) <italic>E. coli</italic> LPS is normally used in these studies, partly because it is the most inflammatory; and (iii) peripheral endotoxin can dramatically increase (‘priming’) or decrease (‘tolerance’) subsequent responses to inflammatory stimuli, including endotoxin, depending on the dose and timing [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p>
<p id="Par43">It is not entirely clear how peripheral endotoxin enters the brain. Endotoxin is found in rat brain in physiological conditions and might cross the blood-brain barrier bound to lipoproteins via lipoprotein transport mechanisms [<xref ref-type="bibr" rid="CR48">48</xref>]. High-dose endotoxin can induce an increase in blood-brain barrier permeability, allowing plasma components into the brain, potentially resulting in neuroinflammation and neurodegeneration, but also potentially allowing endotoxin into the brain [<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref>].</p>
<p id="Par44">Low and medium doses of endotoxin do not change blood-brain barrier permeability and only minimally enter the brain [<xref ref-type="bibr" rid="CR52">52</xref>], suggesting that peripheral LPS may induce brain inflammation indirectly by (i) LPS activation of peripheral nerves acting centrally; (ii) LPS activation of the blood-brain barrier, which then releases cytokines within the brain, or recruiting immune cells into the brain; or (iii) LPS activation of circumventricular organs. The mechanisms of LPS-induced neurodegeneration and the utility of LPS in modelling neurodegenerative disease are reviewed in [<xref ref-type="bibr" rid="CR53">53</xref>]. The effects of peripheral endotoxin on the brain can also be mediated by the induced peripheral cytokines, particularly TNFα and IL-1β, which then induce inflammation within the brain [<xref ref-type="bibr" rid="CR54">54</xref>]. However, sustained brain inflammation in response to blood endotoxin requires brain TLR4, which may be on microglia, endothelium, perivascular macrophages, meninges or circumventricular organs [<xref ref-type="bibr" rid="CR55">55</xref>]. This implies that the longer-term effect of blood endotoxin on the brain is not mediated by blood cytokines, but may be mediated in part by endotoxin activating the above cells to produce cytokines within the brain (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Different species of endotoxin arise from different sources, ending up in the blood or brain. Blood endotoxin increase pro-inflammatory cytokines in blood, and inflammatory activates the blood-brain barrier (BBB) and circumventricular organs (CVO), recruiting leucocytes into the brain and increasing brain cytokines that activate microglia, resulting in synaptic and neuronal loss</p></caption><graphic id="MO2" xlink:href="12974_2019_1564_Fig2_HTML"></graphic></fig></p>
<p id="Par45">Multiple mechanisms have been described by which endotoxin can induce neurodegeneration. Endotoxin stimulates microglia to produce nitric oxide and pro-inflammatory cytokines via activation of TLR4 [<xref ref-type="bibr" rid="CR56">56</xref>]. If LPS is combined with IFNγ (from recruited T cells), then high levels of iNOS are induced in microglia and astrocytes, and the resulting NO can kill neurons when combined with either hypoxia [<xref ref-type="bibr" rid="CR57">57</xref>] or superoxide from the NADPH oxidase [<xref ref-type="bibr" rid="CR58">58</xref>]. However, treatment of glial-neuronal cultures with LPS alone results in little or no neuronal apoptosis or necrosis, but rather progressive loss of neurons over several days due to microglial phagocytosis of stressed-but-viable neurons and blocking the phagocytosis saves the neurons [<xref ref-type="bibr" rid="CR59">59</xref>]. LPS-activated microglia release NO, superoxide and peroxynitrite that stresses the neurons to reversibly expose phosphatidylserine, which is bound by MFG-E8 released from the astrocytes and microglia, and this MFG-E8 (bound to the stressed neurons) also binds the vitronection receptor, which triggers microglial phagocytosis of these neurons [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Engulfment also appears to require UDP released from the stressed neurons to stimulate the P2Y6 receptor on microglia [<xref ref-type="bibr" rid="CR61">61</xref>]. Thus, blocking the P2Y6 receptor, the vitronection receptor or MFG-E8 prevents LPS-induced neuronal loss in culture or in vivo [<xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]. TNFα can also induce microglia to phagocytose neurons in the absence of LPS [<xref ref-type="bibr" rid="CR62">62</xref>].</p>
<p id="Par46">Neuronal loss is often preceded by synaptic loss in neurodegenerative disease, for example in Alzheimer’s disease, and this synaptic loss can be caused by excessive microglial phagocytosis of neurons, driven in part by complement tagging of synapses, triggered by neuroinflammation [<xref ref-type="bibr" rid="CR28">28</xref>]. Peripheral endotoxin can activate the classical complement system in the brain, resulting in neuronal loss that can be prevented in complement C3-deficient mice [<xref ref-type="bibr" rid="CR63">63</xref>]. Peripheral endotoxin can also cause microglial activation and loss of brain synapses, and the endotoxin-binding protein APOE2 can protect against this synaptic loss [<xref ref-type="bibr" rid="CR64">64</xref>]. Synaptic loss may contribute to cognitive deficits in disease, but if excessive might also cause neuronal loss [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
<p id="Par47">High plasma levels of endotoxin can increase permeability of the blood-brain barrier, allowing toxic plasma components, including amyloid β and α-synuclein into the brain [<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref>]. Endotoxin may also promote the production or aggregation of amyloid β [<xref ref-type="bibr" rid="CR66">66</xref>–<xref ref-type="bibr" rid="CR68">68</xref>], tau [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>] and α-synuclein [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. This suggests the possibility that endotoxin synergises with different aggregable proteins to give different neurodegenerative diseases (Fig. <xref ref-type="fig" rid="Fig3">3</xref>).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Endotoxin may give rise to different neurodegenerative disease by synergising with different aggregable proteins to induce neurodegeneration. If endotoxin contributes to multiple different diseases, why are these different diseases different? The solution may be a two-hit hypothesis, where the presence of endotoxin or an aggregable protein is not sufficient alone, but together, they induce neurodegeneration and give rise to different neurodegenerative diseases dependent on the particular aggregable protein present and its distribution in the brain. Note that the presence in the brain of an aggregable protein, such as Aβ, Tau or α-synuclein, is not normally sufficient to induce neurodegeneration</p></caption><graphic id="MO3" xlink:href="12974_2019_1564_Fig3_HTML"></graphic></fig></p>
<p id="Par48">Blood endotoxin may ‘prime’ microglia to neurodegenerative stimuli (such as amyloid β, tau or α-synuclein), or alternatively, neurodegenerative stimuli (such as aggregating amyloid β, tau or α-synuclein) may prime microglia to endotoxin challenge—either way they synergise to induce neurodegeneration [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. There is clinical evidence that systemic inflammation triggers neurodegeneration in brains primed by neurodegenerative disease [<xref ref-type="bibr" rid="CR72">72</xref>]. For example, systemic infections accelerate cognitive decline in Alzheimer’s disease patients [<xref ref-type="bibr" rid="CR73">73</xref>], and systemic endotoxin precipitates brain pathology in mice expressing prions [<xref ref-type="bibr" rid="CR74">74</xref>], APP variants [<xref ref-type="bibr" rid="CR33">33</xref>] or TAU variants [<xref ref-type="bibr" rid="CR69">69</xref>] or mice with α-synuclein injected in the brain [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
<p id="Par49">Conversely, blood endotoxin may induce tolerance and decrease activation of microglia, which may reduce brain protective functions such as phagocytosis of protein aggregate or debris [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. The concepts of microglial ‘activation’, ‘priming’ and ‘tolerance’ are loose, but all are reversible states of microglia, mediated by translational and epigenetic changes. In essence, ‘microglial activation’ refers to increased microglial motility, phagocytosis, cytokine release and oxidant production, while ‘microglial priming’ means the microglia are more sensitive to agents causing activation, and ‘microglial tolerance’ means the microglia are less sensitive to agents causing activation [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In summary, endotoxin can act at muliple steps to promote neurodegeneration (Fig. <xref ref-type="fig" rid="Fig4">4</xref>).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Endotoxin may act at different steps to promote neurodegeneration. (1) Endotoxin may promote aggregates of Aβ, tau, α-synuclein and TDP-43 by inhibiting removal or by increasing production, spread or aggregation (in part by stimulating ROS production). (2) Endotoxin may prime microglia and stress neurons, making them more susceptible to disease-specific agents. (3) Endotoxin may activate microglia, already primed by disease to execute stressed synapses and neurons</p></caption><graphic id="MO4" xlink:href="12974_2019_1564_Fig4_HTML"></graphic></fig></p>
</sec>
<sec id="Sec5">
<title>Endotoxin and Alzheimer’s disease</title>
<p id="Par50">Alzheimer’s disease (AD) is diagnosed by cognitive and memory deficits during life, and amyloid plaques and tau tangles after death, accompanied by neuroinflammation, synapse loss and neuronal loss. AD is also associated with endotoxin in a number of ways [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Mean blood endotoxin levels are increased threefold in AD patients [<xref ref-type="bibr" rid="CR10">10</xref>]. Brain endotoxin levels are increased two- or threefold in AD patients [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>], and endotoxin is also found in AD amyloid plaques [<xref ref-type="bibr" rid="CR79">79</xref>]. Endotoxin can drive amyloid beta production and aggregation [<xref ref-type="bibr" rid="CR66">66</xref>–<xref ref-type="bibr" rid="CR68">68</xref>] and TAU hyperphosphorylation [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Eliminating gut bacteria can reduce plaque load and microglial activation in an amyloid model of AD in mice [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p id="Par51">If AD was in part mediated by endotoxin, then we might expect gene variants associated with AD to interact with endotoxin or endotoxin pathology. The main genetic risk for AD is APOE isoform: APOE2 being protective, APOE3 being neutral and APOE4 being detrimental. Intravenous injection of LPS strongly induces serum ApoE in rodents, and ApoE directly binds LPS, causing LPS to be taken up and degraded by the liver, such that ApoE-deficient mice are more sensitive to LPS toxicity [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Humans with the APOE4 variant are more sensitive to injected LPS than those with APOE3, and similarly, mice with endogenous ApoE replaced with APOE4 are more sensitive to LPS than those replaced with APOE3 [<xref ref-type="bibr" rid="CR83">83</xref>]. Thus, there is a clear and direct link between APOE variants and endotoxin. Sequence variants of the LPS-receptor TLR4 [<xref ref-type="bibr" rid="CR84">84</xref>] and the LPS-binding receptor TREM2 [<xref ref-type="bibr" rid="CR22">22</xref>] are also associated with an increased risk of AD, indicating additional genetic links between AD and endotoxin.</p>
<p id="Par52">People with chronic gum disease (periodontitis) have elevated blood endotoxin [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>], a higher risk of Alzheimer’s disease and a faster rate of cognitive decline [<xref ref-type="bibr" rid="CR87">87</xref>]. The most prevalent bacteria in periodontal diseases are <italic>Porphyromonas gingivalis</italic>. LPS from <italic>P. gingivalis</italic> is less inflammatory than that from <italic>E. coli</italic> on the first encounter; however, on the second encounter, the inflammatory response to <italic>E. coli</italic> is greatly downregulated (‘tolerance’), whereas the response to <italic>P. gingivalis</italic> LPS is not [<xref ref-type="bibr" rid="CR88">88</xref>]. Chronic oral application of <italic>P. gingivalis</italic> or injection of <italic>P. gingivalis</italic> LPS results in brain inflammation and neurodegeneration in wild-type mice [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. There is a large increase in bacterial load and bacterial species in AD brains [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR90">90</xref>], including <italic>P. gingivalis</italic>, which can live intracellularly in glia and neurons [<xref ref-type="bibr" rid="CR91">91</xref>]. The causes and consequences of these brain bacteria are unclear, but they are a potential source of brain endotoxin, and thus of neuroinflammation and neurodegeneration.</p>
</sec>
<sec id="Sec6">
<title>Endotoxin and Parkinson’s disease</title>
<p id="Par53">Parkinson’s disease (PD) is diagnosed by motor dysfunctions in life, and after death by α-synuclein aggregates (Lewy bodies) and loss of dopaminergic neurons in the substantia nigra. During PD, α-synuclein aggregation starts in the gut, and one of the earliest symptoms of PD is gut dysfunction [<xref ref-type="bibr" rid="CR2">2</xref>]. PD patients have increased gastrointestinal permeability [<xref ref-type="bibr" rid="CR92">92</xref>] and LPS binding protein (LBP) [<xref ref-type="bibr" rid="CR92">92</xref>], and a proportion of PD patients have elevated blood endotoxin [<xref ref-type="bibr" rid="CR93">93</xref>]. The gut microbiome of PD patients differs from controls [<xref ref-type="bibr" rid="CR94">94</xref>]. And the gut microbiome affects motor symptoms in an α-synuclein mouse model of PD, such that eliminating gut bacteria prevents motor deficits, while introducing the gut microbiome from PD patients exacerbates pathology [<xref ref-type="bibr" rid="CR95">95</xref>]. Gut colonisation with endotoxin-producing <italic>Helicobacter pylori</italic> is associated with PD [<xref ref-type="bibr" rid="CR96">96</xref>], and eradication of <italic>H. pylori</italic> improved PD symptoms [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>].</p>
<p id="Par54">A single dose of peripheral endotoxin in mice caused increased expression of α-synuclein in neurons of the large intestine, followed by an increase in large intestinal permeability, in a manner similar to that observed in patients with PD [<xref ref-type="bibr" rid="CR99">99</xref>]. Endotoxin increases α-synuclein production by macrophages [<xref ref-type="bibr" rid="CR100">100</xref>] and drives α-synuclein fibrillization [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. A single injection of peripheral endotoxin into wild-type mice and transgenic mice (expressing human A53T mutant α-synuclein) resulted in indistinguishable acute neuroinflammation, but only the transgenic mice treated with endotoxin developed persistent neuroinflammation, aggregated α-synuclein, progressive degeneration of dopamine neurons and Lewy body-like inclusions in nigral neurons [<xref ref-type="bibr" rid="CR101">101</xref>]. This supports a dual-hit hypothesis for PD: elevated endotoxin plus aggregable α-synuclein results in neurodegeneration. However, endotoxin alone is sufficient to induce loss of dopaminergic neurons in the substantia nigra in mice after a delay of several months [<xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref>].</p>
</sec>
<sec id="Sec7">
<title>Endotoxin and other brain pathologies</title>
<p id="Par55">Motor neuron disease is a group of diseases involving neurodegeneration of motor neurons, of which the most common is amyotrophic lateral sclerosis (ALS), which shares genetic and pathological mechanisms with frontotemporal dementia (FTD). In ALS, and many cases of FTD, the motor neurons are filled with abnormal aggregates of TAR DNA-binding protein 43 (TDP-43). Blood endotoxin levels are elevated in ALS patients [<xref ref-type="bibr" rid="CR10">10</xref>], possibly as a result of gut inflammation and microbiome changes [<xref ref-type="bibr" rid="CR102">102</xref>]. Addition of LPS to microglia or astrocytes in culture resulted in TDP-43 mislocalization and aggregation, and addition of peripheral LPS to TDP-43(A315T) transgenic mice resulted in TDP-43 aggregation in vivo [<xref ref-type="bibr" rid="CR103">103</xref>]. This suggests a dual-hit hypothesis for ALS and FTD: increased endotoxin levels plus aggregable TDP-43 results in neurodegeneration.</p>
<p id="Par56">A variety of roles for endotoxin in multiple sclerosis have been suggested, including (i) promoting microglial damage to myelin and (ii) promoting the presentation of myelin antigens [<xref ref-type="bibr" rid="CR104">104</xref>].</p>
<p id="Par57">Plasma endotoxin levels are increased in AIDS, HIV-infected patients and SIV-infected rhesus macaques, as a result of gut-wall damage [<xref ref-type="bibr" rid="CR12">12</xref>]. HIV infection can progress to HIV-associated dementia, and this correlates with plasma endotoxin levels, which may drive monocyte activation and trafficking into the brain [<xref ref-type="bibr" rid="CR105">105</xref>].</p>
<p id="Par58">Chronic alcohol consumption and binge drinking increase serum endotoxin and cytokine levels [<xref ref-type="bibr" rid="CR106">106</xref>], which might contribute to long-term cognitive deficits.</p>
<p id="Par59">Bacterial meningitis can be caused by gram-negative bacteria, such as <italic>Neisseria meningitidis</italic>, infecting the brain meninges, often resulting in long-term cognitive problems, and much of the pathology has been attributed to endotoxin [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
<p id="Par60">Maternal infection is a risk factor for neurodevelopmental disorders such as autism and schizophrenia. A single pre-natal exposure to LPS (of embryos, for example as a result of maternal infection) or early post-natal exposure can result in long-term activation of brain microglia, lasting into adulthood [<xref ref-type="bibr" rid="CR108">108</xref>], and behavioural deficits reminiscent of autism or schizophrenia [<xref ref-type="bibr" rid="CR109">109</xref>]. Serious infections increase the risk of subsequently developing schizophrenia [<xref ref-type="bibr" rid="CR110">110</xref>], and genetic risk factors for schizophrenia increase microglial phagocytosis of synapses [<xref ref-type="bibr" rid="CR111">111</xref>], leading to the idea that schizophrenia is triggered by excessive microglial phagocytosis of synapses during adolescence [<xref ref-type="bibr" rid="CR111">111</xref>], and one potential cause of this is increased endotoxin. Perinatal infections are also associated with autism [<xref ref-type="bibr" rid="CR109">109</xref>], potentially due to dysfunctional microglial phagocytosis of synapses [<xref ref-type="bibr" rid="CR112">112</xref>], which could in principle be driven by endotoxin. Blood endotoxin levels are increased in autism [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
<p id="Par61">Sepsis is often caused by gram-negative bacteria in the blood, and therefore, blood endotoxin levels can be very high (up to 500 pg/ml [<xref ref-type="bibr" rid="CR13">13</xref>]). So, in principle, it is a good test of whether high blood endotoxin can cause neurodegeneration in humans. Almost all patients with sepsis have altered consciousness (confusion progressing to delirium and loss of consciousness), and about half of the people surviving serious sepsis have long-term cognitive deficits (called sepsis-associated encephalopathy) [<xref ref-type="bibr" rid="CR113">113</xref>]. However, it is still unclear that the cognitive deficits are caused by the endotoxin, and it is difficult to extrapolate from a relatively short exposure (days) of high levels of blood endotoxin (as occurs in sepsis) to the long exposure (years) of relatively low blood (or brain) endotoxin that may occur with neurodegenerative disease. Additionally, sepsis is most often caused by bacteria such as <italic>E. coli</italic> or <italic>Pseudomonas aeruginosa</italic> [<xref ref-type="bibr" rid="CR113">113</xref>], both with highly inflammatory LPS lipid A structures (6 to 7 acyl chains), making it difficult to extrapolate to other diseases.</p>
<p id="Par62">Liver failure may provide a better test of whether chronically elevated levels of blood endotoxin can cause neurodegeneration in humans. The liver is the main organ for clearing blood endotoxin, so liver failure, as occurs in cirrhosis, elevates blood endotoxin levels to roughly the same level as occurs in Alzheimer’s disease (Table <xref ref-type="table" rid="Tab1">1</xref>). About half of patients with cirrhosis will develop long-term cognitive deficits (called hepatic encephalopathy), progressing from forgetfulness and confusion to coma. However, although blood endotoxin levels correlate with hepatic encephalopathy, so to do blood ammonia and cytokine levels, which are also potentially causal for the encephalopathy, so we still do not know whether endotoxin causes hepatic encephalopathy [<xref ref-type="bibr" rid="CR114">114</xref>].</p>
</sec>
<sec id="Sec8">
<title>Conclusions</title>
<p id="Par63">Increased endotoxin is associated with neurodegenerative disease, and increased endotoxin can cause neurodegeneration, but whether neurodegenerative disease is caused by increased endotoxin is not known. Testing this causal link depends on determining whether reducing endotoxin levels or endotoxin actions reduces neurodegenerative disease pathology. Possible means to do this and therefore potential treatment targets include (i) changing the gut microbiome to species with less or less-toxic LPS, (ii) reducing intestinal permeability, (iii) reducing peripheral, peridonatal and/or brain infections, (iv) reducing blood endotoxin levels, (v) reducing LPS actions on, or permeability across, the blood-brain barrier, (vi) inhibiting TLR4 or other LPS receptors or (vii) inhibiting endotoxin-induced microglial activation and neurotoxicity.</p>
<p id="Par64">The key tests of the plasma endotoxin theory of neurodegeneration are the following: (a) do plasma endotoxin levels correlate with and/or precede neurodegeneration in relevant diseases, and (b) does lowering plasma endotoxin levels in patients reduce subsequent neurodegeneration. We need larger studies of blood endotoxin levels in a variety of neurodegenerative diseases, and we need longitudinal monitoring over the time course of the diseases. Luckily, monitoring blood endotoxin is relatively easy and cheap. However, it will also be important to know the various species of endotoxins in these diseases. Developing treatments that lower blood endotoxin levels in the long term will be difficult, but is likely to be useful for a wide range of conditions, beyond neurodegeneration. LBP, APOE2, polymyxin B or antibodies against LPS could be infused into blood to lower LPS levels, but may be impractical long term. Albumin dialysis is already used to remove endotoxin in patients with liver failure [<xref ref-type="bibr" rid="CR115">115</xref>] and might be used to test whether lowering endotoxin is beneficial for neurodegeneration, but applying albumin dialysis for several years would be challenging. Vaccines against LPS might be feasible as a longer-term solution.</p>
<p id="Par65">Animal models will also be important: firstly, to work out how endotoxin causes neurodegeneration; secondly, to test means of blocking endotoxin-induced neurodegeneration; and thirdly, to test potential treatments to lower endotoxin.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AD</term>
<def>
<p id="Par2">Alzheimer’s disease</p>
</def>
</def-item>
<def-item>
<term>AIDS</term>
<def>
<p id="Par3">Acquired immune deficiency syndrome</p>
</def>
</def-item>
<def-item>
<term>ALS</term>
<def>
<p id="Par4">Amyotrophic lateral sclerosis</p>
</def>
</def-item>
<def-item>
<term>APOE</term>
<def>
<p id="Par5">Apolipoprotein E</p>
</def>
</def-item>
<def-item>
<term>APP</term>
<def>
<p id="Par6">Amyloid precursor protein</p>
</def>
</def-item>
<def-item>
<term>BBB</term>
<def>
<p id="Par7">Blood-brain barrier</p>
</def>
</def-item>
<def-item>
<term>C3</term>
<def>
<p id="Par8">Complement component 3</p>
</def>
</def-item>
<def-item>
<term>CVO</term>
<def>
<p id="Par9">Circumventricular organs</p>
</def>
</def-item>
<def-item>
<term>EU</term>
<def>
<p id="Par10">Endotoxin units</p>
</def>
</def-item>
<def-item>
<term>FTD</term>
<def>
<p id="Par11">Frontotemporal dementia</p>
</def>
</def-item>
<def-item>
<term>HDL</term>
<def>
<p id="Par12">High-density lipoproteins</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p id="Par13">Interleukin</p>
</def>
</def-item>
<def-item>
<term>iNOS</term>
<def>
<p id="Par14">Inducible nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term>LAL</term>
<def>
<p id="Par15">Limulus amebocyte lysate</p>
</def>
</def-item>
<def-item>
<term>LBP</term>
<def>
<p id="Par16">Lipopolysaccharide binding protein</p>
</def>
</def-item>
<def-item>
<term>LPS</term>
<def>
<p id="Par17">Lipopolysaccharide</p>
</def>
</def-item>
<def-item>
<term>MD2</term>
<def>
<p id="Par18">Myeloid differentiation factor 2</p>
</def>
</def-item>
<def-item>
<term>MFG-E8</term>
<def>
<p id="Par19">Milk fat globulin E8</p>
</def>
</def-item>
<def-item>
<term>NO</term>
<def>
<p id="Par20">Nitric oxide</p>
</def>
</def-item>
<def-item>
<term>PD</term>
<def>
<p id="Par21">Parkinson’s disease</p>
</def>
</def-item>
<def-item>
<term>RAGE</term>
<def>
<p id="Par22">Receptor for advanced glycation endproducts</p>
</def>
</def-item>
<def-item>
<term>STAT1</term>
<def>
<p id="Par23">Signal transducer and activator of transcription 1</p>
</def>
</def-item>
<def-item>
<term>TDP-43</term>
<def>
<p id="Par24">TAR DNA-binding protein 43</p>
</def>
</def-item>
<def-item>
<term>TLR4</term>
<def>
<p id="Par25">Toll-like receptor 4</p>
</def>
</def-item>
<def-item>
<term>TNF</term>
<def>
<p id="Par26">Tumour necrosis factor</p>
</def>
</def-item>
<def-item>
<term>TREM2</term>
<def>
<p id="Par27">Triggering receptor expressed on myeloid cells</p>
</def>
</def-item>
<def-item>
<term>UDP</term>
<def>
<p id="Par28">Uridine diphosphate</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Author’s contributions</title>
<p>The author read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>My own research in this field has been funded by the Wellcome Trust (Grant RG50995, 084645/Z/08/Z), Medical Research Council, UK (Grant MR/L010593), Alzheimer’s Research UK, and European Union, and I received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115976 (PHAGO).</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par66">Not applicable.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par67">Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par68">The author declares that he/she has no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>VanItallie</surname>
<given-names>TB</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: innate immunity gone awry?</article-title>
<source/>Metabolism.
          <year>2017</year>
<volume>69S</volume>
<fpage>S41</fpage>
<lpage>S49</lpage>
<pub-id pub-id-type="doi">10.1016/j.metabol.2017.01.014</pub-id>
<pub-id pub-id-type="pmid">28129888</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeiffer</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Gastrointestinal dysfunction in Parkinson’s disease</article-title>
<source/>Curr Treat Options Neurol
          <year>2018</year>
<volume>20</volume>
<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1007/s11940-018-0539-9</pub-id>
<pub-id pub-id-type="pmid">30361783</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Needham</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Trent</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis</article-title>
<source/>Nat Rev Microbiol
          <year>2013</year>
<volume>11</volume>
<fpage>467</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1038/nrmicro3047</pub-id>
<pub-id pub-id-type="pmid">23748343</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hajjar</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Human toll-like receptor 4 recognizes host-specific LPS modifications</article-title>
<source/>Nat Immunol
          <year>2002</year>
<volume>3</volume>
<fpage>354</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1038/ni777</pub-id>
<pub-id pub-id-type="pmid">11912497</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vatanen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kostic</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>d'Hennezel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Siljander</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Franzosa</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Yassour</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans</article-title>
<source/>Cell.
          <year>2016</year>
<volume>165</volume>
<fpage>1551</fpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.05.056</pub-id>
<pub-id pub-id-type="pmid">27259157</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sender</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Milo</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Revised estimates for the number of human and bacteria cells in the body</article-title>
<source/>PLoS Biol
          <year>2016</year>
<volume>14</volume>
<fpage>e1002533</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1002533</pub-id>
<pub-id pub-id-type="pmid">27541692</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nádházi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Takáts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Offenmüller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bertók</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Plasma endotoxin level of healthy donors</article-title>
<source/>Acta Microbiol Immunol Hung
          <year>2002</year>
<volume>49</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1556/AMicr.49.2002.1.15</pub-id>
<pub-id pub-id-type="pmid">12073822</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiedermann</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kiechl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dunzendorfer</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study</article-title>
<source/>J Am Coll Cardiol
          <year>1999</year>
<volume>34</volume>
<fpage>1975</fpage>
<lpage>1981</lpage>
<pub-id pub-id-type="doi">10.1016/S0735-1097(99)00448-9</pub-id>
<pub-id pub-id-type="pmid">10588212</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalash</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vovk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aukhil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wallet</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Shaddox</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Influence of periodontal therapy on systemic lipopolysaccharides in children with localized aggressive periodontitis</article-title>
<source/>Pediatr Dent
          <year>2015</year>
<volume>37</volume>
<fpage>35</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">26531074</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Gascon</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)</article-title>
<source/>J Neuroimmunol
          <year>2009</year>
<volume>206</volume>
<fpage>121</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.09.017</pub-id>
<pub-id pub-id-type="pmid">19013651</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raparelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Basili</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carnevale</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Napoleone</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Del Ben</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nocella</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bartimoccia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lucidi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Talerico</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Riggio</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Violi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Low-grade endotoxemia and platelet activation in cirrhosis</article-title>
<source/>Hepatology.
          <year>2017</year>
<volume>65</volume>
<fpage>571</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1002/hep.28853</pub-id>
<pub-id pub-id-type="pmid">27641757</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenchley</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schacker</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Asher</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Silvestri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbial translocation is a cause of systemic immune activation in chronic HIV infection</article-title>
<source/>Nat Med
          <year>2006</year>
<volume>12</volume>
<fpage>1365</fpage>
<lpage>1371</lpage>
<pub-id pub-id-type="doi">10.1038/nm1511</pub-id>
<pub-id pub-id-type="pmid">17115046</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opal</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Scannon</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>White</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Palardy</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Parejo</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Pribble</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Lemke</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock</article-title>
<source/>J Infect Dis
          <year>1999</year>
<volume>180</volume>
<fpage>1584</fpage>
<lpage>1589</lpage>
<pub-id pub-id-type="doi">10.1086/315093</pub-id>
<pub-id pub-id-type="pmid">10515819</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erridge</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Attina</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spickett</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation</article-title>
<source/>Am J Clin Nutr
          <year>2007</year>
<volume>86</volume>
<fpage>1286</fpage>
<lpage>1292</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/86.5.1286</pub-id>
<pub-id pub-id-type="pmid">17991637</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandiego</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gallezot</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Pittman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nabulsi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Matuskey</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hannestad</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cosgrove</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Imaging robust microglial activation after lipopolysaccharide administration in humans with PET</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2015</year>
<volume>112</volume>
<fpage>12468</fpage>
<lpage>12473</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1511003112</pub-id>
<pub-id pub-id-type="pmid">26385967</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Animal models of sepsis</article-title>
<source/>Virulence
          <year>2014</year>
<volume>5</volume>
<fpage>143</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.4161/viru.26083</pub-id>
<pub-id pub-id-type="pmid">24022070</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Innate immune programing by endotoxin and its pathological consequences</article-title>
<source/>Front Immunol
          <year>2015</year>
<volume>5</volume>
<fpage>680</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2014.00680</pub-id>
<pub-id pub-id-type="pmid">25610440</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryant</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Spring</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Gangloff</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The molecular basis of the host response to lipopolysaccharide</article-title>
<source/>Nat Rev Microbiol
          <year>2010</year>
<volume>8</volume>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1038/nrmicro2266</pub-id>
<pub-id pub-id-type="pmid">19946286</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Dynamic lipopolysaccharide transfer cascade to TLR4/MD2 complex via LBP and CD14</article-title>
<source/>BMB Rep
          <year>2017</year>
<volume>50</volume>
<fpage>55</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.5483/BMBRep.2017.50.2.011</pub-id>
<pub-id pub-id-type="pmid">28115037</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfalzgraff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weindl</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Intracellular lipopolysaccharide sensing as a potential therapeutic target for sepsis</article-title>
<source/>Trends Pharmacol Sci
          <year>2019</year>
<volume>40</volume>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2019.01.001</pub-id>
<pub-id pub-id-type="pmid">30691865</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harashima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tsuneyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Munesue</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Motoyoshi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Septic shock is associated with receptor for advanced glycation end products ligation of LPS</article-title>
<source/>J Immunol
          <year>2011</year>
<volume>186</volume>
<fpage>3248</fpage>
<lpage>3257</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1002253</pub-id>
<pub-id pub-id-type="pmid">21270403</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daws</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Sullam</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Niemi</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Tchao</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Seaman</surname>
<given-names>WE</given-names>
</name>
</person-group>
<article-title>Pattern recognition by TREM-2: binding of anionic ligands</article-title>
<source/>J Immunol
          <year>2003</year>
<volume>171</volume>
<fpage>594</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.171.2.594</pub-id>
<pub-id pub-id-type="pmid">12847223</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hampton</surname>
<given-names>RY</given-names>
</name>
<name>
<surname>Golenbock</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Penman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krieger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raetz</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Recognition and plasma clearance of endotoxin by scavenger receptors</article-title>
<source/>Nature.
          <year>1991</year>
<volume>352</volume>
<fpage>342</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1038/352342a0</pub-id>
<pub-id pub-id-type="pmid">1852209</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Jong</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide</article-title>
<source/>J Exp Med
          <year>1986</year>
<volume>164</volume>
<fpage>1876</fpage>
<lpage>1888</lpage>
<pub-id pub-id-type="doi">10.1084/jem.164.6.1876</pub-id>
<pub-id pub-id-type="pmid">3537192</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Jong</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chad</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kabbash</surname>
<given-names>LG</given-names>
</name>
</person-group>
<article-title>CR3 (CD11b/CD18) expresses one binding site for Arg-Gly-Asp-containing peptides and a second site for bacterial lipopolysaccharide</article-title>
<source/>J Exp Med
          <year>1989</year>
<volume>169</volume>
<fpage>175</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1084/jem.169.1.175</pub-id>
<pub-id pub-id-type="pmid">2462607</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fenton</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Golenbock</surname>
<given-names>DT</given-names>
</name>
</person-group>
<article-title>LPS-binding proteins and receptors</article-title>
<source/>J Leukoc Biol
          <year>1998</year>
<volume>64</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1002/jlb.64.1.25</pub-id>
<pub-id pub-id-type="pmid">9665271</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Complement receptor 3 mediates NADPH oxidase activation and dopaminergic neurodegeneration through a Src-Erk-dependent pathway</article-title>
<source/>Redox Biol
          <year>2018</year>
<volume>14</volume>
<fpage>250</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2017.09.017</pub-id>
<pub-id pub-id-type="pmid">28978491</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beja-Glasser</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Nfonoyim</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Frouin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ramakrishnan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title>
<source/>Science.
          <year>2016</year>
<volume>352</volume>
<fpage>712</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1126/science.aad8373</pub-id>
<pub-id pub-id-type="pmid">27033548</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurley</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Endotoxemia: methods of detection and clinical correlates</article-title>
<source/>Clin Microbiol Rev
          <year>1995</year>
<volume>8</volume>
<fpage>268</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1128/CMR.8.2.268</pub-id>
<pub-id pub-id-type="pmid">7621402</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuele</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Orsi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Boso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Broglia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brondino</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Barale</surname>
<given-names>F</given-names>
</name>
<name>
<surname>di Nemi</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Politi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Low-grade endotoxemia in patients with severe autism</article-title>
<source/>Neurosci Lett
          <year>2010</year>
<volume>471</volume>
<fpage>162</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.01.033</pub-id>
<pub-id pub-id-type="pmid">20097267</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayashree</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bibin</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Prabhu</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes</article-title>
<source/>Mol Cell Biochem
          <year>2014</year>
<volume>388</volume>
<fpage>203</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-013-1911-4</pub-id>
<pub-id pub-id-type="pmid">24347174</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaros</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Maitra</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Causes and consequences of low grade endotoxemia and inflammatory diseases</article-title>
<source/>Front Biosci (Schol Ed)
          <year>2013</year>
<volume>5</volume>
<fpage>754</fpage>
<lpage>765</lpage>
<pub-id pub-id-type="doi">10.2741/S405</pub-id>
<pub-id pub-id-type="pmid">23277084</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wendeln</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Degenhardt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaurani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gertig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ulas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Häsler</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Skodras</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blank</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Staszewski</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Centeno</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Capece</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kerimoglu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Staufenbiel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schultze</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prinz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jucker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neher</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Innate immune memory in the brain shapes neurological disease hallmarks</article-title>
<source/>Nature.
          <year>2018</year>
<volume>556</volume>
<fpage>332</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-018-0023-4</pub-id>
<pub-id pub-id-type="pmid">29643512</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Romero-Tejeda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sirignano</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Naturally occurring subclinical endotoxemia in humans alters adaptive and innate immune functions through reduced MAPK and increased STAT1 phosphorylation</article-title>
<source/>J Immunol
          <year>2016</year>
<volume>196</volume>
<fpage>668</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1501888</pub-id>
<pub-id pub-id-type="pmid">26643479</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chae</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Beyond urinary tract infections (UTIs) and delirium: a systematic review of UTIs and neuropsychiatric disorders</article-title>
<source/>J Psychiatr Pract
          <year>2015</year>
<volume>21</volume>
<fpage>402</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1097/PRA.0000000000000105</pub-id>
<pub-id pub-id-type="pmid">26554322</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bischoff</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Barbara</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Buurman</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intestinal permeability – a new target for disease prevention and therapy</article-title>
<source/>BMC Gastroenterol
          <year>2014</year>
<volume>14</volume>
<fpage>189</fpage>
<pub-id pub-id-type="doi">10.1186/s12876-014-0189-7</pub-id>
<pub-id pub-id-type="pmid">25407511</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenchley</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Douek</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Microbial translocation across the GI tract</article-title>
<source/>Annu Rev Immunol
          <year>2012</year>
<volume>30</volume>
<fpage>149</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075001</pub-id>
<pub-id pub-id-type="pmid">22224779</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vreugdenhil</surname>
<given-names>ACE</given-names>
</name>
<name>
<surname>Rousseau</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons</article-title>
<source/>J Immunol
          <year>2003</year>
<volume>170</volume>
<fpage>1399</fpage>
<lpage>1405</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.170.3.1399</pub-id>
<pub-id pub-id-type="pmid">12538700</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Mates</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cheplowitz</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blood-borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein</article-title>
<source/>J Immunol
          <year>2016</year>
<volume>197</volume>
<fpage>2390</fpage>
<lpage>2399</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1600702</pub-id>
<pub-id pub-id-type="pmid">27534554</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Oosten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rensen</surname>
<given-names>PCN</given-names>
</name>
<name>
<surname>Van Amersfoort</surname>
<given-names>ES</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>8820</fpage>
<lpage>8824</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M009915200</pub-id>
<pub-id pub-id-type="pmid">11136731</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lumsden</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kutner</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis</article-title>
<source/>Hepatology.
          <year>1988</year>
<volume>8</volume>
<fpage>232</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1002/hep.1840080207</pub-id>
<pub-id pub-id-type="pmid">3281884</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Block</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Breese</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Knapp</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>FT</given-names>
</name>
</person-group>
<article-title>Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration</article-title>
<source/>Glia.
          <year>2007</year>
<volume>55</volume>
<fpage>453</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20467</pub-id>
<pub-id pub-id-type="pmid">17203472</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J-S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration</article-title>
<source/>Glia.
          <year>2013</year>
<volume>61</volume>
<fpage>855</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22479</pub-id>
<pub-id pub-id-type="pmid">23536230</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tufekci</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Genc</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Genc</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The endotoxin-induced neuroinflammation model of Parkinson’s disease</article-title>
<source/>Parkinsons Dis
          <year>2011</year>
<volume>2011</volume>
<fpage>487450</fpage>
<pub-id pub-id-type="pmid">21331154</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zakaria</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wan Yaacob</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Othman</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Al-Rahbi</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer’s disease</article-title>
<source/>Physiol Res
          <year>2017</year>
<volume>66</volume>
<fpage>553</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="pmid">28406691</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couch</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Alvarez-Erviti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sibson</surname>
<given-names>NR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>166</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-166</pub-id>
<pub-id pub-id-type="pmid">22122884</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms that underlie the dynamic adaptation of innate monocyte memory to varying stimulant strength of TLR ligands</article-title>
<source/>Front Immunol
          <year>2016</year>
<volume>7</volume>
<fpage>497</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00497</pub-id>
<pub-id pub-id-type="pmid">27891130</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas-Caraveo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sayd</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maus</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Caso</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>JLM</given-names>
</name>
<name>
<surname>García-Bueno</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leza</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport mechanism in physiological conditions</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>13113</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-13302-6</pub-id>
<pub-id pub-id-type="pmid">29030613</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vutukuri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brunkhorst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kestner</surname>
<given-names>R-I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption</article-title>
<source/>J Neurochem
          <year>2018</year>
<volume>144</volume>
<fpage>172</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.14236</pub-id>
<pub-id pub-id-type="pmid">29023711</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varatharaj</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>The blood-brain barrier in systemic inflammation</article-title>
<source/>Brain Behav Immun
          <year>2017</year>
<volume>60</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2016.03.010</pub-id>
<pub-id pub-id-type="pmid">26995317</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeger</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Dohgu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sultana</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: a mechanism for inflammation in the progression of Alzheimer’s disease</article-title>
<source/>Brain Behav Immun
          <year>2009</year>
<volume>23</volume>
<fpage>507</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2009.01.017</pub-id>
<pub-id pub-id-type="pmid">19486646</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banks</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Minimal penetration of lipopolysaccharide across the murine blood-brain barrier</article-title>
<source/>Brain Behav Immun
          <year>2010</year>
<volume>24</volume>
<fpage>102</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2009.09.001</pub-id>
<pub-id pub-id-type="pmid">19735725</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batista</surname>
<given-names>CRA</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Candelario-Jalil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fiebich</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>ACP</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration</article-title>
<source/>Int J Mol Sci
          <year>2019</year>
<volume>20</volume>
<fpage>E2293</fpage>
<pub-id pub-id-type="doi">10.3390/ijms20092293</pub-id>
<pub-id pub-id-type="pmid">31075861</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skelly</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Hennessy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dansereau</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1β, TNF-α and IL-6 challenges in C57BL/6 mice</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e69123</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069123</pub-id>
<pub-id pub-id-type="pmid">23840908</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakravarty</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Herkenham</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>1788</fpage>
<lpage>1796</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4268-04.2005</pub-id>
<pub-id pub-id-type="pmid">15716415</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinsner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boveri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hareng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Coecke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bal-Price</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide</article-title>
<source/>J Neurochem
          <year>2006</year>
<volume>99</volume>
<fpage>596</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04085.x</pub-id>
<pub-id pub-id-type="pmid">16879708</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Borutaite</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Moncada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death</article-title>
<source/>J Neurosci Res
          <year>2005</year>
<volume>79</volume>
<fpage>208</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.20285</pub-id>
<pub-id pub-id-type="pmid">15558752</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration</article-title>
<source/>J Neuroinflammation
          <year>2005</year>
<volume>2</volume>
<fpage>20</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-2-20</pub-id>
<pub-id pub-id-type="pmid">16156895</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neher</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Neniskyte</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bal-Price</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tolkovsky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death</article-title>
<source/>J Immunol
          <year>2011</year>
<volume>186</volume>
<fpage>4973</fpage>
<lpage>4983</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1003600</pub-id>
<pub-id pub-id-type="pmid">21402900</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fricker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neher</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Théry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tolkovsky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>MFG-E8 mediates primary phagocytosis of viable neurons during neuroinflammation</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>2657</fpage>
<lpage>2666</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4837-11.2012</pub-id>
<pub-id pub-id-type="pmid">22357850</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neher</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Neniskyte</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hornik</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Inhibition of UDP/P2Y6 purinergic signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo</article-title>
<source/>Glia.
          <year>2014</year>
<volume>62</volume>
<fpage>1463</fpage>
<lpage>1475</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22693</pub-id>
<pub-id pub-id-type="pmid">24838858</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neniskyte</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Vilalta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Tumour necrosis factor alpha-induced neuronal loss is mediated by microglial phagocytosis</article-title>
<source/>FEBS Lett
          <year>2014</year>
<volume>588</volume>
<fpage>2952</fpage>
<lpage>2956</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2014.05.046</pub-id>
<pub-id pub-id-type="pmid">24911209</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodea</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Linnartz-Gerlach</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kopatz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sinkkonen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Musgrove</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kaoma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vallar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Monte</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Balling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Neurodegeneration by activation of the microglial complement-phagosome pathway</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>8546</fpage>
<lpage>8556</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5002-13.2014</pub-id>
<pub-id pub-id-type="pmid">24948809</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nwabuisi-Heath</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dumanis</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rebeck</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>LaDu</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>APOE genotype alters glial activation and loss of synaptic markers in mice</article-title>
<source/>Glia.
          <year>2012</year>
<volume>60</volume>
<fpage>559</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22289</pub-id>
<pub-id pub-id-type="pmid">22228589</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fricker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tolkovsky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Borutaite</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Neuronal cell death</article-title>
<source/>Physiol Rev
          <year>2018</year>
<volume>98</volume>
<fpage>813</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00011.2017</pub-id>
<pub-id pub-id-type="pmid">29488822</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Yuk</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation</article-title>
<source/>J Neuroinflammation
          <year>2008</year>
<volume>5</volume>
<fpage>37</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-5-37</pub-id>
<pub-id pub-id-type="pmid">18759972</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gioglio</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation?</article-title>
<source/>J Alzheimers Dis
          <year>2014</year>
<volume>39</volume>
<fpage>169</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-131394</pub-id>
<pub-id pub-id-type="pmid">24150108</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gardner</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Eimerbrink</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide</article-title>
<source/>Neuroscience.
          <year>2016</year>
<volume>331</volume>
<fpage>72</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.06.007</pub-id>
<pub-id pub-id-type="pmid">27320209</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhaskar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Konerth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kokiko-Cochran</surname>
<given-names>ON</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of tau pathology by the microglial fractalkine receptor</article-title>
<source/>Neuron
          <year>2010</year>
<volume>68</volume>
<fpage>19</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2010.08.023</pub-id>
<pub-id pub-id-type="pmid">20920788</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exposure to bacterial endotoxin generates a distinct strain of α- synuclein fibril</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>30891</fpage>
<pub-id pub-id-type="doi">10.1038/srep30891</pub-id>
<pub-id pub-id-type="pmid">27488222</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>LTT</given-names>
</name>
<name>
<surname>Burlak</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein</article-title>
<source/>Proc Natl Acad Sci
          <year>2016</year>
<volume>113</volume>
<fpage>9587</fpage>
<lpage>9592</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1610099113</pub-id>
<pub-id pub-id-type="pmid">27482083</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Microglia and neurodegeneration: the role of systemic inflammation</article-title>
<source/>Glia.
          <year>2013</year>
<volume>61</volume>
<fpage>71</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22350</pub-id>
<pub-id pub-id-type="pmid">22674585</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zotova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Woolford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Culliford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
</person-group>
<article-title>Systemic inflammation and disease progression in Alzheimer disease</article-title>
<source/>Neurology.
          <year>2009</year>
<volume>73</volume>
<fpage>768</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b6bb95</pub-id>
<pub-id pub-id-type="pmid">19738171</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Campion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lunnon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Deacon</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Rawlins</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
</person-group>
<article-title>Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease</article-title>
<source/>Biol Psychiatry
          <year>2009</year>
<volume>65</volume>
<fpage>304</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.07.024</pub-id>
<pub-id pub-id-type="pmid">18801476</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaafsma</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>van Zomeren</surname>
<given-names>KC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-lasting pro-inflammatory suppression of microglia by LPS-preconditioning is mediated by RelB-dependent epigenetic silencing</article-title>
<source/>Brain Behav Immun
          <year>2015</year>
<volume>48</volume>
<fpage>205</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2015.03.013</pub-id>
<pub-id pub-id-type="pmid">25843371</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardon</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide hyporesponsiveness: protective or damaging response to the brain?</article-title>
<source/>Romanian J Morphol Embryol
          <year>2015</year>
<volume>56</volume>
<fpage>903</fpage>
<lpage>913</lpage>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stamova</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review</article-title>
<source/>Front Aging Neurosci
          <year>2018</year>
<volume>10</volume>
<fpage>42</fpage>
<pub-id pub-id-type="doi">10.3389/fnagi.2018.00042</pub-id>
<pub-id pub-id-type="pmid">29520228</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jaber</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lukiw</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus</article-title>
<source/>Front Cell Infect Microbiol
          <year>2017</year>
<volume>7</volume>
<fpage>318</fpage>
<pub-id pub-id-type="doi">10.3389/fcimb.2017.00318</pub-id>
<pub-id pub-id-type="pmid">28744452</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stamova</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L-W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gram-negative bacterial molecules associate with Alzheimer disease pathology</article-title>
<source/>Neurology.
          <year>2016</year>
<volume>87</volume>
<fpage>2324</fpage>
<lpage>2332</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000003391</pub-id>
<pub-id pub-id-type="pmid">27784770</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minter</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ringus</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Oyler-Castrillo</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>30028</fpage>
<pub-id pub-id-type="doi">10.1038/srep30028</pub-id>
<pub-id pub-id-type="pmid">27443609</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rensen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Oosten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bilt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Eck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuiper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berkel</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo</article-title>
<source/>J Clin Invest
          <year>1997</year>
<volume>99</volume>
<fpage>2438</fpage>
<lpage>2445</lpage>
<pub-id pub-id-type="doi">10.1172/JCI119427</pub-id>
<pub-id pub-id-type="pmid">9153287</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Oosten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rensen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Van Amersfoort</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Van Eck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Dam</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Breve</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Panet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Berkel</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Kuiper</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>8820</fpage>
<lpage>8824</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M009915200</pub-id>
<pub-id pub-id-type="pmid">11136731</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gale</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mikacenic</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Rafaels</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Murray Dudenkov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madenspacher</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Draper</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Aloor</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Azzam</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blackshear</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Calvano</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wurfel</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Fessler</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>APOε4 is associated with enhanced in vivo innate immune responses in human subjects</article-title>
<source/>J Allergy Clin Immunol
          <year>2014</year>
<volume>134</volume>
<fpage>127</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2014.01.032</pub-id>
<pub-id pub-id-type="pmid">24655576</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TF</given-names>
</name>
</person-group>
<article-title>Sequence variants of toll like receptor 4 and late-onset Alzheimer’s disease</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e50771</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0050771</pub-id>
<pub-id pub-id-type="pmid">23272070</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahaidi</surname>
<given-names>VY</given-names>
</name>
<name>
<surname>Kowolik</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Eckert</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Endotoxemia and the host systemic response during experimental gingivitis</article-title>
<source/>J Clin Periodontol
          <year>2011</year>
<volume>38</volume>
<fpage>412</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-051X.2011.01710.x</pub-id>
<pub-id pub-id-type="pmid">21320151</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaddox</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wiedey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Calderon</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bimstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bidwell</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Zapert</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Aukhil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wallet</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Local inflammatory markers and systemic endotoxin in aggressive periodontitis</article-title>
<source/>J Dent Res
          <year>2011</year>
<volume>90</volume>
<fpage>1140</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="doi">10.1177/0022034511413928</pub-id>
<pub-id pub-id-type="pmid">21730256</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ide</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sussams</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Culliford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ibbett</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Raybould</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Puenter</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Teeling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Periodontitis and cognitive decline in Alzheimer’s disease</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<fpage>e0151081</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0151081</pub-id>
<pub-id pub-id-type="pmid">26963387</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Michalek</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli</article-title>
<source/>J Immunol
          <year>2001</year>
<volume>167</volume>
<fpage>5278</fpage>
<lpage>5285</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.167.9.5278</pub-id>
<pub-id pub-id-type="pmid">11673543</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Porphyromonas gingivalis lipopolysaccharide induces cognitive dysfunction, mediated by neuronal inflammation via activation of the TLR4 signaling pathway in C57BL/6 mice</article-title>
<source/>J Neuroinflammation
          <year>2018</year>
<volume>15</volume>
<fpage>37</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-1052-x</pub-id>
<pub-id pub-id-type="pmid">29426327</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emery</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Shoemark</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Batstone</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Waterfall</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Coghill</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cerajewska</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>M</given-names>
</name>
<name>
<surname>West</surname>
<given-names>NX</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>16S rRNA next generation sequencing analysis shows bacteria in Alzheimer’s post-mortem brain</article-title>
<source/>Front Aging Neurosci
          <year>2017</year>
<volume>9</volume>
<fpage>195</fpage>
<pub-id pub-id-type="doi">10.3389/fnagi.2017.00195</pub-id>
<pub-id pub-id-type="pmid">28676754</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilievski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zuchowska</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Ragozzino</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Aljewari</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>O'Brien-Simpson</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice</article-title>
<source/>PLoS One
          <year>2018</year>
<volume>13</volume>
<fpage>e0204941</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0204941</pub-id>
<pub-id pub-id-type="pmid">30281647</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsyth</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e28032</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0028032</pub-id>
<pub-id pub-id-type="pmid">22145021</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<mixed-citation publication-type="other">Wijeyekoon RS. The biological basis of heterogeneity in Parkinson’s disease - insights from an innate immune perspective. Doctoral thesis, University of Cambridge, 2018, doi: 10.17863/CAM.30569</mixed-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheperjans</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aho</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>PAB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gut microbiota are related to Parkinson’s disease and clinical phenotype</article-title>
<source/>Mov Disord
          <year>2015</year>
<volume>30</volume>
<fpage>350</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26069</pub-id>
<pub-id pub-id-type="pmid">25476529</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Thron</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease</article-title>
<source/>Cell.
          <year>2016</year>
<volume>167</volume>
<fpage>1469</fpage>
<lpage>1480</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.11.018</pub-id>
<pub-id pub-id-type="pmid">27912057</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>Xiaoli</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Huazhen</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Yili</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Dongfeng</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Hong</given-names>
</name>
</person-group>
<article-title>Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases</article-title>
<source/>Helicobacter
          <year>2017</year>
<volume>22</volume>
<issue>5</issue>
<fpage>e12398</fpage>
<pub-id pub-id-type="doi">10.1111/hel.12398</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<mixed-citation publication-type="other">Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben‐Shlomo Y. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev. 2011;11:CD008453.</mixed-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Eradication of Helicobacter pylori infection might improve clinical status of patients with Parkinson’s disease, especially on bradykinesia</article-title>
<source/>Clin Neurol Neurosurg
          <year>2017</year>
<volume>160</volume>
<fpage>101</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1016/j.clineuro.2017.07.003</pub-id>
<pub-id pub-id-type="pmid">28704778</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Carvey</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Keshavarzian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bakay</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease</article-title>
<source/>Mov Disord
          <year>2014</year>
<volume>29</volume>
<fpage>999</fpage>
<lpage>1009</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25736</pub-id>
<pub-id pub-id-type="pmid">24898698</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanji</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Imaizumi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages</article-title>
<source/>Pathol Int
          <year>2002</year>
<volume>52</volume>
<fpage>572</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="doi">10.1046/j.1440-1827.2002.01385.x</pub-id>
<pub-id pub-id-type="pmid">12406186</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kam</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease</article-title>
<source/>Environ Health Perspect
          <year>2011</year>
<volume>119</volume>
<fpage>807</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="doi">10.1289/ehp.1003013</pub-id>
<pub-id pub-id-type="pmid">21245015</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Gut inflammation and dysbiosis in human motor neuron disease</article-title>
<source/>Physiol Rep
          <year>2017</year>
<volume>5</volume>
<fpage>e13443</fpage>
<pub-id pub-id-type="doi">10.14814/phy2.13443</pub-id>
<pub-id pub-id-type="pmid">28947596</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correia</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Julien</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Inflammation induces TDP-43 mislocalization and aggregation</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0140248</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0140248</pub-id>
<pub-id pub-id-type="pmid">26444430</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hänninen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Infections in MS: an innate immunity perspective</article-title>
<source/>Acta Neurol Scand
          <year>2017</year>
<volume>136</volume>
<issue>Suppl 201</issue>
<fpage>10</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12838</pub-id>
<pub-id pub-id-type="pmid">29068495</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ancuta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kamat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kunstman</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Autissier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wurcel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zaman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mefford</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morgello</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wolinsky</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gabuzda</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<fpage>e2516</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002516</pub-id>
<pub-id pub-id-type="pmid">18575590</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gattu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e96864</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0096864</pub-id>
<pub-id pub-id-type="pmid">24828436</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandtzaeg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van Deuren</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Classification and pathogenesis of meningococcal infections</article-title>
<source/>Methods Mol Biol
          <year>2012</year>
<volume>799</volume>
<fpage>21</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-61779-346-2_2</pub-id>
<pub-id pub-id-type="pmid">21993637</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Loughlin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pakan</surname>
<given-names>JMP</given-names>
</name>
<name>
<surname>Yilmazer-Hanke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>KW</given-names>
</name>
</person-group>
<article-title>Acute in utero exposure to lipopolysaccharide induces inflammation in the pre- and postnatal brain and alters the glial cytoarchitecture in the developing amygdala</article-title>
<source/>J Neuroinflammation
          <year>2017</year>
<volume>14</volume>
<fpage>212</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-0981-8</pub-id>
<pub-id pub-id-type="pmid">29096641</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Custódio</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Mello</surname>
<given-names>BSF</given-names>
</name>
<name>
<surname>Filho</surname>
<given-names>AJMC</given-names>
</name>
<name>
<surname>de Carvalho Lima</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Miyajima</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Réus</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>Vasconcelos</surname>
<given-names>SMM</given-names>
</name>
<name>
<surname>Barichello</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>de Lucena</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Macedo</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Neonatal immune challenge with lipopolysaccharide triggers long-lasting sex- and age-related behavioral and immune/neurotrophic alterations in mice: relevance to autism spectrum disorders</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<volume>55</volume>
<fpage>3775</fpage>
<lpage>3788</lpage>
<pub-id pub-id-type="pmid">28536974</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benros</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Nordentoft</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study</article-title>
<source/>Am J Psychiatry
          <year>2011</year>
<volume>168</volume>
<fpage>1303</fpage>
<lpage>1310</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11030516</pub-id>
<pub-id pub-id-type="pmid">22193673</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bialas</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>de Rivera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Kamitaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tooley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Presumey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Doren</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Genovese</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Handsaker</surname>
<given-names>RE</given-names>
</name>
<collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>B</given-names>
</name>
<name>
<surname>McCarroll</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Schizophrenia risk from complex variation of complement component 4</article-title>
<source/>Nature.
          <year>2016</year>
<volume>530</volume>
<fpage>177</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1038/nature16549</pub-id>
<pub-id pub-id-type="pmid">26814963</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Paolicelli</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Sforazzini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weinhard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bolasco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vyssotski</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bifone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ragozzino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<fpage>400</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3641</pub-id>
<pub-id pub-id-type="pmid">24487234</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widmann</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Long-term cerebral consequences of sepsis</article-title>
<source/>Lancet Neurol
          <year>2014</year>
<volume>13</volume>
<fpage>630</fpage>
<lpage>636</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70017-1</pub-id>
<pub-id pub-id-type="pmid">24849863</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sarin</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy</article-title>
<source/>Dig Liver Dis
          <year>2012</year>
<volume>44</volume>
<fpage>1027</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="doi">10.1016/j.dld.2012.07.002</pub-id>
<pub-id pub-id-type="pmid">22883217</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>García Martínez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bendjelid</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Artificial liver support systems: what is new over the last decade?</article-title>
<source/>Ann Intensive Care
          <year>2018</year>
<volume>8</volume>
<fpage>109</fpage>
<pub-id pub-id-type="doi">10.1186/s13613-018-0453-z</pub-id>
<pub-id pub-id-type="pmid">30443736</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>